{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:28:23Z","timestamp":1771046903535,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Photodynamic therapy (PDT) is known to occlude choroidal neovascularisation selectively, and there have been several reports on its adverse effects on the normal choroid and retinal pigment epithelium, resulting in decreased vision.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective interventional case series aimed to investigate the changes in visual acuity and retinal thickness in the immediate post-treatment period after half-fluence PDT, administered alone or with anti-vascular endothelial growth factor and steroids, in 29 eyes (26 patients) with neovascular age-related macular degeneration. The patients\u2019 best-corrected visual acuity (BCVA) and central foveal thickness (CFT) on optical coherence tomography images were measured 1\u2009day, 1\u2009week, and 1\u2009month post-treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared to the pre-treatment CFT (270.38\u2009\u03bcm), the mean CFT was significantly increased 1\u2009day post-treatment (387.07\u2009\u03bcm, <jats:italic>P<\/jats:italic>\u00a0=\u20090.001), which then started to decrease, with a mean CFT of 269.32\u2009\u03bcm (<jats:italic>P<\/jats:italic>\u00a0=\u20090.516) at 1\u2009week, and of 240.66\u2009\u03bcm (<jats:italic>P<\/jats:italic>\u00a0=\u20090.066) at 1\u2009month post-treatment. All CFT increases were due to the accumulation of subretinal fluid (SRF), rather than the intraretinal or subretinal pigment epithelium fluid. Relative to the pre-treatment BCVA (0.59 logMAR), the mean BCVA at 1\u2009day (0.74 logMAR, <jats:italic>P<\/jats:italic>\u00a0=\u20090.005) and 1\u2009week (0.75 logMAR, <jats:italic>P<\/jats:italic>\u00a0=\u20090.002) post-treatment was significantly deteriorated; however, it recovered to 0.62 logMAR at 1\u2009month. The patterns of change in CFT and BCVA did not differ according to treatment modality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Half-fluence PDT resulted in accumulation of SRF in the immediate post-treatment period; this damage mostly recovered within a week, and the BCVA was restored within a month.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-021-01867-w","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T18:02:46Z","timestamp":1614016966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Transient accumulation of subretinal fluid after half-fluence photodynamic therapy in neovascular age-related macular degeneration"],"prefix":"10.1186","volume":"21","author":[{"given":"Min Ho","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoo-Ri","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2860-2340","authenticated-orcid":false,"given":"Ji Hun","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"1867_CR1","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.ophtha.2017.05.035","volume":"124","author":"JM Colijn","year":"2017","unstructured":"Colijn JM, Buitendijk GHS, Prokofyeva E, Alves D, Cachulo ML, Khawaja AP, et al. Prevalence of age-related macular degeneration in europe: the past and the future. Ophthalmology. 2017;124:1753\u201363.","journal-title":"Ophthalmology."},{"key":"1867_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","volume":"53","author":"CW Wong","year":"2016","unstructured":"Wong CW, Yanagi Y, Lee WK, Ogura Y, Yeo I, Wong TY, et al. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res. 2016;53:107\u201339.","journal-title":"Prog Retin Eye Res"},{"key":"1867_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/APO.0b013e31827ff5bc","volume":"2","author":"LS Lim","year":"2013","unstructured":"Lim LS, Cheung CM, Wong TY. Asian age-related macular degeneration: current concepts and gaps in knowledge. Asia Pac J Ophthalmol (Phila.). 2013;2:32\u201341.","journal-title":"Asia Pac J Ophthalmol (Phila.)"},{"key":"1867_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0002-9394(01)00967-9","volume":"131","author":"Verteporfin In Photodynamic Therapy Study Group","year":"2001","unstructured":"Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541\u201360.","journal-title":"Am J Ophthalmol"},{"key":"1867_CR5","doi-asserted-by":"crossref","unstructured":"Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999;117:1329\u201345.","DOI":"10.1001\/archopht.117.10.1329"},{"key":"1867_CR6","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/sj.bjc.6690271","volume":"79","author":"VH Fingar","year":"1999","unstructured":"Fingar VH, Kik PK, Haydon PS, Cerrito PB, Tseng M, Abang E, et al. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br J Cancer. 1999;79:1702\u20138.","journal-title":"Br J Cancer"},{"key":"1867_CR7","first-page":"Cd005139","volume":"3","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2019;3:Cd005139.","journal-title":"Cochrane Database Syst Rev"},{"key":"1867_CR8","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina (Phila). 2012;32:1453\u201364.","journal-title":"Retina (Phila)"},{"key":"1867_CR9","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135:1206\u201313.","journal-title":"JAMA Ophthalmol"},{"key":"1867_CR10","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1136\/bjophthalmol-2015-307802","volume":"100","author":"P Rishi","year":"2016","unstructured":"Rishi P, Rishi E, Bhende M, Agarwal V, Vyas CH, Valiveti M, et al. Comparison of photodynamic therapy, ranibizumab\/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single Centre. Br J Ophthalmol. 2016;100:1337\u201340.","journal-title":"Br J Ophthalmol"},{"key":"1867_CR11","first-page":"830","volume":"43","author":"U Schmidt-Erfurth","year":"2002","unstructured":"Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002;43:830\u201341.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1867_CR12","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1136\/bjo.85.9.1086","volume":"85","author":"UE Schnurrbusch","year":"2001","unstructured":"Schnurrbusch UE, Welt K, Horn LC, Wiedemann P, Wolf S. Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy. Br J Ophthalmol. 2001;85:1086\u201391.","journal-title":"Br J Ophthalmol"},{"key":"1867_CR13","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00417-005-0237-7","volume":"244","author":"S Mennel","year":"2006","unstructured":"Mennel S, Peter S, Meyer CH, Thumann G. Effect of photodynamic therapy on the function of the outer blood-retinal barrier in an in vitro model. Graefes Arch Clin Exp Ophthalmol (Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie). 2006;244:1015\u201321.","journal-title":"Graefes Arch Clin Exp Ophthalmol (Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie)"},{"key":"1867_CR14","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/S0161-6420(13)31079-3","volume":"101","author":"U Schmidt-Erfurth","year":"1994","unstructured":"Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology. 1994;101:1953\u201361.","journal-title":"Ophthalmology."},{"key":"1867_CR15","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ajo.2010.10.030","volume":"151","author":"I Maruko","year":"2011","unstructured":"Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T. Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2011;151:594\u2013603 e591.","journal-title":"Am J Ophthalmol"},{"key":"1867_CR16","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1177\/112067210801800429","volume":"18","author":"G Lo Giudice","year":"2008","unstructured":"Lo Giudice G, De Belvis V, Piermarocchi S, Galan A, Prosdocimo G. Acute visual loss and chorioretinal infarction after photodynamic therapy combined with intravitreal triamcinolone. Eur J Ophthalmol. 2008;18:652\u20135.","journal-title":"Eur J Ophthalmol"},{"key":"1867_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.preteyeres.2013.09.003","volume":"37","author":"P Nowak-Sliwinska","year":"2013","unstructured":"Nowak-Sliwinska P, van den Bergh H, Sickenberg M, Koh AH. Photodynamic therapy for polypoidal choroidal vasculopathy. Prog Retin Eye Res. 2013;37:182\u201399.","journal-title":"Prog Retin Eye Res"},{"key":"1867_CR18","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.ajo.2005.04.041","volume":"140","author":"S Mennel","year":"2005","unstructured":"Mennel S, Meyer CH, Eggarter F, Peter S. Transient serous retinal detachment in classic and occult choroidal neovascularization after photodynamic therapy. Am J Ophthalmol. 2005;140:758\u201360.","journal-title":"Am J Ophthalmol"},{"key":"1867_CR19","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1001\/archopht.117.9.1177","volume":"117","author":"U Schmidt-Erfurth","year":"1999","unstructured":"Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol. 1999;117:1177\u201387.","journal-title":"Arch Ophthalmol"},{"key":"1867_CR20","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0002-9394(00)00813-8","volume":"131","author":"F Gelisken","year":"2001","unstructured":"Gelisken F, Inhoffen W, Partsch M, Schneider U, Kreissig I. Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization. Am J Ophthalmol. 2001;131:518\u201320.","journal-title":"Am J Ophthalmol"},{"key":"1867_CR21","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.ajo.2006.07.037","volume":"142","author":"CP Shah","year":"2006","unstructured":"Shah CP, Hsu J, Garg SJ, Fischer DH, Kaiser R. Retinal pigment epithelial tear after intravitreal bevacizumab injection. Am J Ophthalmol. 2006;142:1070\u20132.","journal-title":"Am J Ophthalmol"},{"key":"1867_CR22","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/sj.eye.6703018","volume":"21","author":"A Jalil","year":"2007","unstructured":"Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Eye (Lond). 2007;21:1541.","journal-title":"Eye (Lond)"},{"key":"1867_CR23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/IAE.0b013e318280769c","volume":"33","author":"E Smretschnig","year":"2013","unstructured":"Smretschnig E, Ansari-Shahrezaei S, Hagen S, Glittenberg C, Krebs I, Binder S. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy. Retina (Phila.). 2013;33:316\u201323.","journal-title":"Retina (Phila.)."},{"key":"1867_CR24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/bjophthalmol-2016-308921","volume":"101","author":"T Izumi","year":"2017","unstructured":"Izumi T, Koizumi H, Maruko I, Takahashi Y, Sonoda S, Sakamoto T, et al. Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy. Br J Ophthalmol. 2017;101:433\u20137.","journal-title":"Br J Ophthalmol"},{"key":"1867_CR25","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.ajo.2007.08.017","volume":"144","author":"PJ Rosenfeld","year":"2007","unstructured":"Rosenfeld PJ, Boyer DS, Bressler NM, Fish G, Grizzard WS, Hao Y, et al. Verteporfin therapy of subfoveal occult choroidal neovascularization in AMD using delayed light application: one-year results of the VALIO study. Am J Ophthalmol. 2007;144:970\u20132.","journal-title":"Am J Ophthalmol"},{"key":"1867_CR26","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1001\/archopht.1991.01080090044025","volume":"109","author":"Macular Photocoagulation Study Group","year":"1991","unstructured":"Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch of Ophthalmol. 1991;109:1220\u201331.","journal-title":"Arch of Ophthalmol"},{"key":"1867_CR27","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1167\/iovs.02-0604","volume":"44","author":"S Michels","year":"2003","unstructured":"Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci. 2003;44:2147\u201354.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1867_CR28","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1016\/j.ophtha.2005.09.007","volume":"112","author":"U Schmidt-Erfurth","year":"2005","unstructured":"Schmidt-Erfurth U, Niemeyer M, Geitzenauer W, Michels S. Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmology. 2005;112:2061\u20139.","journal-title":"Ophthalmology."},{"key":"1867_CR29","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S0002-9394(02)01566-0","volume":"134","author":"AH Rogers","year":"2002","unstructured":"Rogers AH, Martidis A, Greenberg PB, Puliafito CA. Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization. Am J Ophthalmol. 2002;134:566\u201376.","journal-title":"Am J Ophthalmol"},{"key":"1867_CR30","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/IAE.0b013e318042d3b0","volume":"27","author":"O Tatar","year":"2007","unstructured":"Tatar O, Adam A, Shinoda K, Yoeruek E, Szurman P, Bopp S, et al. Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to age-related macular degeneration. Retina (Phila.). 2007;27:713\u201323.","journal-title":"Retina (Phila.)"},{"issue":"Suppl 1","key":"1867_CR31","first-page":"41","volume":"224","author":"F Bandello","year":"2010","unstructured":"Bandello F, Battaglia Parodi M, Tremolada G, Lattanzio R, De Benedetto U, Iacono P. Steroids as part of combination treatment: the future for the management of macular edema? Int J Ophthalmol. 2010;224(Suppl 1):41\u20135.","journal-title":"Int J Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-01867-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-021-01867-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-01867-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T18:03:14Z","timestamp":1614016994000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-021-01867-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1867"],"URL":"https:\/\/doi.org\/10.1186\/s12886-021-01867-w","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]},"assertion":[{"value":"31 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective interventional case series was approved by the Institutional Review Board (IRB) of Ajou University Medical Centre in Suwon, South Korea. This study was conducted in accordance with the tenets of the Declaration of Helsinki and the relevant guidelines and regulations by the IRB of the Ajou University Medical Centre. The need for informed consent was waived in view of the retrospective nature of the study by the IRB of Ajou University Medical Centre.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests regarding the publication of this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}